Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17097339 | 0.99 | HTR6 (0.49) | HTR6IRAK4TLR8CA12CA1 | |
| SCHEMBL17102235 | 0.88 | HTT (0.39) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL17102222 | 0.86 | HTR6 (0.47) | HTR6CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL17097296 | 0.85 | HTR6 (0.47) | HTR6DRD3HTR2A | |
| SCHEMBL17097093 | 0.84 | HTR6 (0.45) | HTR6 | |
| SCHEMBL16703404 | 0.83 | HTR6 (0.53) | HTR6CYP3A4 | |
| SCHEMBL17120392 | 0.83 | HTR6 (0.49) | HTR6CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL16697723 | 0.82 | HTR6 (0.52) | HTR6CYP3A4 | |
| SCHEMBL16703642 | 0.82 | HTR6 (0.52) | HTR6CYP3A4HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL17097132 | 0.82 | HTR6 (0.49) | HTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 47/4885IRAK4 2207/4885TLR8 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.